---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-130436"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T18:48:50.232449+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123

## Summary
- IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.
- Non-binding LOI with Kineta to acquire KVA12123 VISTA antibody via merger; definitive agreement targeted Q4 2024.
- Cash runway expected to fund operations late into H2 2025; $31M from Kintara merger plus $5M for Kineta exclusivity.
- Hired Peter O'Neill as VP Clinical Operations and Michael Krsulich as Head of Quality Assurance.
- REM-001 photodynamic therapy study for cutaneous metastatic breast cancer enrollment expected to complete Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-130436
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/0000950170-24-130436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/hura-20241125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-130436
- JSON: https://secwatch.observer/filing/0000950170-24-130436.json
- Plain text: https://secwatch.observer/filing/0000950170-24-130436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.